Published in Biochemistry on May 18, 2007
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol (2008) 1.82
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 1.66
Structural and functional insights into RAGE activation by multimeric S100B. EMBO J (2007) 1.59
Structural basis for ligand recognition and activation of RAGE. Structure (2010) 1.50
Role of advanced glycation end products in cellular signaling. Redox Biol (2014) 1.36
RAGE signaling in inflammation and arterial aging. Front Biosci (Landmark Ed) (2009) 1.35
The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med (2009) 1.35
RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis (2009) 1.31
Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol (2010) 1.22
Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam (2013) 1.22
S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem (2011) 1.22
Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem (2010) 1.19
RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med (2013) 1.15
Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med (2012) 1.07
Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem Biol (2013) 1.07
Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem (2010) 1.05
sRAGE induces human monocyte survival and differentiation. J Immunol (2010) 1.05
Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem (2011) 1.04
RAGE: a new frontier in chronic airways disease. Br J Pharmacol (2012) 1.04
Relating form and function of EF-hand calcium binding proteins. Acc Chem Res (2011) 0.99
Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids (2010) 0.98
The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS One (2014) 0.93
Oligomerization interface of RAGE receptor revealed by MS-monitored hydrogen deuterium exchange. PLoS One (2013) 0.91
Large scale isolation and purification of soluble RAGE from lung tissue. Protein Expr Purif (2008) 0.90
A capture method based on the VC1 domain reveals new binding properties of the human receptor for advanced glycation end products (RAGE). Redox Biol (2016) 0.89
Solution structure of the soluble receptor for advanced glycation end products (sRAGE). J Biol Chem (2011) 0.87
The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant. J Biol Chem (2011) 0.87
S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regeneration. PLoS One (2012) 0.87
The S100B/RAGE Axis in Alzheimer's Disease. Cardiovasc Psychiatry Neurol (2010) 0.86
Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem (2012) 0.86
Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis. PLoS One (2012) 0.83
Combinatorial library of improved peptide aptamers, CLIPs to inhibit RAGE signal transduction in mammalian cells. PLoS One (2013) 0.81
Estrogen replacement therapy in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules via a RAGE-related process. Am J Physiol Heart Circ Physiol (2009) 0.81
Structural insights into calcium-bound S100P and the V domain of the RAGE complex. PLoS One (2014) 0.80
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases. Diagnostics (Basel) (2015) 0.79
Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation. J Biol Chem (2016) 0.77
Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling. Structure (2016) 0.76
Effects of bone marrow MSCs transfected with sRAGE on the intervention of HMGB1 induced immuno-inflammatory reaction. Int J Clin Exp Pathol (2015) 0.76
The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice. Amyloid (2015) 0.75
AGE-RAGE interaction in the TGFβ2-mediated epithelial to mesenchymal transition of human lens epithelial cells. Glycoconj J (2016) 0.75
Influence of nonenzymatic posttranslational modifications on constitution, oligomerization and receptor binding of S100A12. PLoS One (2014) 0.75
Blocking the Interactions between Calcium-Bound S100A12 Protein and the V Domain of RAGE Using Tranilast. PLoS One (2016) 0.75
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem (2017) 0.75
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc Natl Acad Sci U S A (1997) 13.28
The program XEASY for computer-supported NMR spectral analysis of biological macromolecules. J Biomol NMR (1995) 12.25
A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci (2003) 9.25
Stereochemical quality of protein structure coordinates. Proteins (1992) 9.18
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng (1993) 5.47
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
Improving biosensor analysis. J Mol Recognit (2000) 4.83
Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem (1991) 4.82
ESyPred3D: Prediction of proteins 3D structures. Bioinformatics (2002) 4.72
The immunoglobulin fold. Structural classification, sequence patterns and common core. J Mol Biol (1994) 4.43
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 3.64
The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta (2000) 3.33
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
S100 proteins: structure, functions and pathology. Front Biosci (2002) 3.28
Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem (1999) 3.12
Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science (1999) 3.03
Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem (2000) 2.78
Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature (1998) 2.65
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem (2003) 2.05
Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb (1994) 2.05
Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem (2004) 1.95
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol (2005) 1.83
Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.82
Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol (2005) 1.70
N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry (1996) 1.63
The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett (2003) 1.60
Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev (2002) 1.56
N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem (2002) 1.51
Global analysis of a macromolecular interaction measured on BIAcore. Biochem Biophys Res Commun (1996) 1.42
Regulation of cell migration by amphoterin. J Cell Sci (2000) 1.41
Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem (2006) 1.40
Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev (2002) 1.37
The L1CAM extracellular region: a multi-domain protein with modular and cooperative binding modes. Front Biosci (2003) 1.30
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism (2006) 1.26
Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. Biochim Biophys Acta (2006) 1.24
RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab (2000) 1.24
Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res (2003) 1.18
The crystal structure of human MRP14 (S100A9), a Ca(2+)-dependent regulator protein in inflammatory process. J Mol Biol (2002) 1.17
Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol (1997) 1.16
Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys (2003) 1.12
The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J Cell Biol (1988) 1.08
The three-dimensional structure of Ca(2+)-bound calcyclin: implications for Ca(2+)-signal transduction by S100 proteins. Structure (1998) 1.07
The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr (2002) 1.06
TROSY NMR with partially deuterated proteins. J Biomol NMR (2001) 1.06
S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner. Mol Cell Biol (2003) 1.03
Intracellular Ca2+ and Zn2+ levels regulate the alternative cell density-dependent secretion of S100B in human glioblastoma cells. J Biol Chem (2001) 1.02
RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res (2004) 0.95
Insights into S100 target specificity examined by a new interaction between S100A11 and annexin A2. Biochemistry (2006) 0.93
Monitoring of S100 homodimerization and heterodimeric interactions by the yeast two-hybrid system. Microsc Res Tech (2003) 0.92
A structural basis for S100 protein specificity derived from comparative analysis of apo and Ca(2+)-calcyclin. J Mol Biol (2002) 0.91
Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris. Biochem Biophys Res Commun (2006) 0.90
S100B proteins that lack one or both cysteine residues can induce inflammatory responses in astrocytes and microglia. Neurochem Int (2001) 0.88
The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant (1996) 0.87
Thermodynamic stability of a kappaI immunoglobulin light chain: relevance to multiple myeloma. Biophys J (2005) 0.86
Purification, crystallization and preliminary X-ray diffraction studies on human Ca2+-binding protein S100B. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.84
Expression and purification of recombinant human receptor for advanced glycation endproducts in Escherichia coli. Protein Expr Purif (2006) 0.83
Crystal structure of a T cell receptor Valpha11 (AV11S5) domain: new canonical forms for the first and second complementarity determining regions. J Mol Biol (2001) 0.79
Metal chelation and inhibition of bacterial growth in tissue abscesses. Science (2008) 4.55
S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun (2004) 3.38
S100 proteins: structure, functions and pathology. Front Biosci (2002) 3.28
Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci (2013) 3.11
Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation (2013) 2.66
Nutrient metal sequestration by calprotectin inhibits bacterial superoxide defense, enhancing neutrophil killing of Staphylococcus aureus. Cell Host Microbe (2011) 2.66
Zinc sequestration by the neutrophil protein calprotectin enhances Salmonella growth in the inflamed gut. Cell Host Microbe (2012) 2.66
Structural insights into the U-box, a domain associated with multi-ubiquitination. Nat Struct Biol (2003) 2.26
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol (2002) 2.24
The basic cleft of RPA70N binds multiple checkpoint proteins, including RAD9, to regulate ATR signaling. Mol Cell Biol (2008) 2.17
Mass spectrometry: a tool for enhanced detection of hemoglobin variants. Clin Chem (2007) 2.11
Structure of an E3:E2~Ub complex reveals an allosteric mechanism shared among RING/U-box ligases. Mol Cell (2012) 2.07
Function of a conserved checkpoint recruitment domain in ATRIP proteins. Mol Cell Biol (2007) 2.02
Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta (2008) 2.00
S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol (2008) 1.82
Novel aspects of calmodulin target recognition and activation. Eur J Biochem (2003) 1.81
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
Target selectivity in EF-hand calcium binding proteins. Biochim Biophys Acta (2004) 1.72
An iron-sulfur cluster in the C-terminal domain of the p58 subunit of human DNA primase. J Biol Chem (2007) 1.71
The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther (2006) 1.67
Physical interaction between replication protein A and Rad51 promotes exchange on single-stranded DNA. J Biol Chem (2004) 1.65
Molecular basis for manganese sequestration by calprotectin and roles in the innate immune response to invading bacterial pathogens. Proc Natl Acad Sci U S A (2013) 1.64
Structural and functional insights into RAGE activation by multimeric S100B. EMBO J (2007) 1.59
Independent and coordinated functions of replication protein A tandem high affinity single-stranded DNA binding domains. J Biol Chem (2003) 1.59
An EF-hand in the sodium channel couples intracellular calcium to cardiac excitability. Nat Struct Mol Biol (2004) 1.59
Human Sgt1 binds HSP90 through the CHORD-Sgt1 domain and not the tetratricopeptide repeat domain. J Biol Chem (2004) 1.52
Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J Cell Biol (2003) 1.51
Structural basis for ligand recognition and activation of RAGE. Structure (2010) 1.50
Insights into hRPA32 C-terminal domain--mediated assembly of the simian virus 40 replisome. Nat Struct Mol Biol (2005) 1.50
S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem (2007) 1.49
Distinct migratory behavior of early- and late-born neurons derived from the cortical ventricular zone. J Comp Neurol (2004) 1.47
Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration. PLoS Pathog (2012) 1.47
Calcium-modulated S100 protein-phospholipid interactions. An NMR study of calbindin D9k and DPC. Biochemistry (2005) 1.46
Structural mechanisms of DNA replication, repair, and recombination. J Biol Chem (2004) 1.46
The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem (2005) 1.44
Structural and functional analysis of essential pre-mRNA splicing factor Prp19p. Mol Cell Biol (2005) 1.42
S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res (2009) 1.42
Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J Biol Chem (2009) 1.39
The Prp19 U-box crystal structure suggests a common dimeric architecture for a class of oligomeric E3 ubiquitin ligases. Biochemistry (2006) 1.38
Calcium-dependent regulation of the voltage-gated sodium channel hH1: intrinsic and extrinsic sensors use a common molecular switch. Proc Natl Acad Sci U S A (2006) 1.36
The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol (2005) 1.34
Solution NMR structure of Apo-calmodulin in complex with the IQ motif of human cardiac sodium channel NaV1.5. J Mol Biol (2010) 1.32
Solution NMR structure of the C-terminal EF-hand domain of human cardiac sodium channel NaV1.5. J Biol Chem (2008) 1.32
Structure of the Ca2+/S100B/NDR kinase peptide complex: insights into S100 target specificity and activation of the kinase. Biochemistry (2003) 1.30
Novel calmodulin mutations associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet (2014) 1.27
Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants. Circ Res (2014) 1.27
Structural mechanism of RPA loading on DNA during activation of a simple pre-replication complex. EMBO J (2006) 1.25
S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol (2009) 1.24
Functional Interactions between Distinct Sodium Channel Cytoplasmic Domains through the Action of Calmodulin. J Biol Chem (2009) 1.22
Insights into eukaryotic DNA priming from the structure and functional interactions of the 4Fe-4S cluster domain of human DNA primase. Proc Natl Acad Sci U S A (2010) 1.21
RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol (2013) 1.21
The presence of an iron-sulfur cluster in adenosine 5'-phosphosulfate reductase separates organisms utilizing adenosine 5'-phosphosulfate and phosphoadenosine 5'-phosphosulfate for sulfate assimilation. J Biol Chem (2002) 1.19
Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett (2005) 1.19
NADH oxidation by the Na+-translocating NADH:quinone oxidoreductase from Vibrio cholerae: functional role of the NqrF subunit. J Biol Chem (2004) 1.19
Checkpoint kinase ATR promotes nucleotide excision repair of UV-induced DNA damage via physical interaction with xeroderma pigmentosum group A. J Biol Chem (2009) 1.19
Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun (2003) 1.19
S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim Biophys Acta (2007) 1.19
Direct ubiquitination of beta-catenin by Siah-1 and regulation by the exchange factor TBL1. J Biol Chem (2010) 1.18
MntABC and MntH contribute to systemic Staphylococcus aureus infection by competing with calprotectin for nutrient manganese. Infect Immun (2013) 1.17
The EF-hand domain: a globally cooperative structural unit. Protein Sci (2002) 1.17
Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun (2008) 1.17
Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci (2008) 1.15
Structural basis for DNA binding by replication initiator Mcm10. Structure (2008) 1.14
Molecular cloning and characterization of the human S100A14 gene encoding a novel member of the S100 family. Genomics (2002) 1.13
A new structural framework for integrating replication protein A into DNA processing machinery. Nucleic Acids Res (2013) 1.12
S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun (2004) 1.11
In support of the BMRB. Nat Struct Mol Biol (2012) 1.09
Unique features in the C-terminal domain provide caltractin with target specificity. J Mol Biol (2003) 1.09
Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene. Oncogene (2004) 1.09
NMR analysis of the architecture and functional remodeling of a modular multidomain protein, RPA. J Am Chem Soc (2009) 1.08
Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med (2012) 1.07
Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem Biol (2013) 1.07
Alpha4 is a ubiquitin-binding protein that regulates protein serine/threonine phosphatase 2A ubiquitination. Biochemistry (2010) 1.06
Mitochondrial matrix calcium is an activating signal for hormone secretion. Cell Metab (2011) 1.06
An update of the S100 nomenclature. Biochim Biophys Acta (2006) 1.05
Biochemical and structural domain analysis of xeroderma pigmentosum complementation group C protein. Biochemistry (2006) 1.05
Structural dynamics and single-stranded DNA binding activity of the three N-terminal domains of the large subunit of replication protein A from small angle X-ray scattering. Biochemistry (2010) 1.04
Structure of the S100A6 complex with a fragment from the C-terminal domain of Siah-1 interacting protein: a novel mode for S100 protein target recognition. Biochemistry (2008) 1.04
Oxidant-induced formation of a neutral flavosemiquinone in the Na+-translocating NADH:Quinone oxidoreductase (Na+-NQR) from Vibrio cholerae. Biochim Biophys Acta (2008) 1.04
Implication of extracellular zinc exclusion by recombinant human calprotectin (MRP8 and MRP14) from target cells in its apoptosis-inducing activity. Mediators Inflamm (2002) 1.03
Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci (2005) 1.03
A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Anal Biochem (2011) 1.03
RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget (2014) 1.03
Engineering and design of ligand-induced conformational change in proteins. Curr Opin Struct Biol (2002) 1.02
Localization and function of the membrane-bound riboflavin in the Na+-translocating NADH:quinone oxidoreductase (Na+-NQR) from Vibrio cholerae. J Biol Chem (2010) 1.02
Ca2+ -dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+ -ATPase2a and phospholamban in the human heart. Biochem Biophys Res Commun (2003) 1.02
Structure of the regulatory apparatus of a calcium-dependent protein kinase (CDPK): a novel mode of calmodulin-target recognition. J Mol Biol (2005) 1.01
Structural and functional characterization of the monomeric U-box domain from E4B. Biochemistry (2010) 1.01
Calmodulin interacts with the V2 vasopressin receptor: elimination of binding to the C terminus also eliminates arginine vasopressin-stimulated elevation of intracellular calcium. J Biol Chem (2004) 1.00
Calcium, troponin, calmodulin, S100 proteins: from myocardial basics to new therapeutic strategies. Biochem Biophys Res Commun (2007) 1.00